Synthesis and in vitro activity of new tetrahydronaphtho[1,2-b]azepine derivatives against Trypanosoma cruzi and Leishmania chagasi parasites

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 8, 2009, Pages 2360-2363

  Palma, Alirio ^a   Yépes, Andrés Felipe ^a   Leal, Sandra Milena ^b   Coronado, Carlos Andrés ^b   Escobar, Patricia ^b  

^a UNIVERSIDAD INDUSTRIAL DE SANTANDER   (Colombia)

^b Centro de Investigación de Enfermedades Tropicales   (Colombia)

Author keywords

1,4 Epoxytetrahydronaphtho 1,2 b azepines; Anti parasitic agents; Chagas' disease; Drug discovery; Leishmania chagasi; Tetrahydronaphtho 1,2 b azepines; Trypanosoma cruzi

Indexed keywords

1,4 EPOXY 2,3,4,5 TETRAHYDRONAPHTHO[1,2 B]AZEPINE DERIVATIVE; 2 (4' BROMOPHENYL) 4 HYDROXYTETRAHYDRONAPHTHO[1,2 B]AZEPINE; 3' BROMOPHENYL 1,4 EPOXYTETRAHYDRONAPHTHO[1,2 B]AZEPINE; 4 HYDROXY 2,3,4,5 TETRAHYDRONAPHTHO[1,2 B]AZEPINE DERIVATIVE; 4' CHLOROPHENYL 1,4 EPOXYTETRAHYDRONAPHTHO[1,2 B]AZEPINE; ANTIPARASITIC AGENT; TETRAHYDRONAPHTHO[1,2 B]AZEPINE DERIVATIVE; UNCLASSIFIED DRUG;

AMASTIGOTE; ANIMAL CELL; ARTICLE; CYTOTOXICITY; DRUG ACTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LEISHMANIA CHAGASI; MACROPHAGE; NONHUMAN; TRYPANOSOMA CRUZI;

ANIMALS; AZEPINES; CELL LINE, TUMOR; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; HUMANS; LEISHMANIA INFANTUM; MACROPHAGES; TETRAHYDRONAPHTHALENES; TRYPANOSOMA CRUZI; VERO CELLS;

LEISHMANIA DONOVANI CHAGASI; MAMMALIA; TRYPANOSOMA CRUZI;

EID: 63349106395     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.05.013     Document Type: Article

References (27)

1. Burri C., and Brun R. Parasitol. Res. 90 (2003) 49
2. Perez-Victoria F.J., Castanys S., and Gamarro F. Antimicrob. Agents Chemother. 47 (2003) 2397
3. Naula Ch., Parsons M., and Mottram J.C. Biochim. Biophys. Acta 1754 (2005) 151
4. Urbina J.A., and Docampo R. Trends Parasitol. 19 (2003) 495
5. Croft S.L., and Coombs G.H. Trends Parasitol. 19 (2003) 502
6. Ouellette M., Drummelsmith J., and Papadopoulou B. Drug Resist. Updat. 7 (2004) 257
7. Shimada Y., Taniguchi N., Matsuhisa A., Sakamoto K., Yatsu T., and Tanaka A. Chem. Pharm. Bull. 48 (2000) 1644
8. Kakefuda A., Tsukada J., Kusayama T., Tahara A., and Tsukamoto Sh. Bioorg. Med. Chem. Lett. (2002) 229
9. Morita M., Ohkubo-Suzuki A., Takahashi T., Nagashima A., Sawada Y., Ohkawa T., Nishimura Sh., and Kita Y. Drug Dev. Res. 60 (2003) 241
10. Tsunoda T., Yamazaki A., Mase T., and Sakamoto Sh. Org. Process Res. Dev. 9 (2005) 593
11. Tsunoda T., Yamazaki A., Iwamoto H., and Sakamoto Sh. Org. Process Res. Dev. 7 (2003) 883
12. Matthews J.M., Greco M.N., Hecker L.R., Hoekstra W.J., Andrade-Gordon P., de Garavilla L., Demarest K.T., Ericson E., Gunnet J.W., Hageman W., Look R., Moore J.B., and Maryanoff B.E. Bioorg. Med. Chem. Lett. (2003) 753
13. Martinez A., Castro A., Dorronsoro I., and Alonso M. Med. Res. Rev. 22 (2002) 373
14. Schultz C., Link A., Leost M., Zaharevitz D.W., Gussio R., Sausville E.A., Meijer L., and Kunick C. J. Med. Chem. 42 (1999) 2909
15. Sielecki T.M., Boylan J.F., Benfield P.A., and Trainor G.L. J. Med. Chem. 43 (2000) 1
16. Kunick C., Schultz C., Lemcke T., Zaharevitz D.W., Gussio R., Jalluri R.K., Sausville E.A., Leost M., and Meijer L. Bioorg. Med. Chem. Lett. (2000) 567
17. Schoen W.R., Pisano J.M., Prendergast K., Wyvratt Jr. M.J., Fisher M.H., Cheng K., Chan W.W.-S., Butler B., Smith R.G., and Ball R.G. J. Med. Chem. 37 (1994) 897
18. DeVita R.J., Bochis R., Frontier A.J., Kotliar A., Fisher M.H., Schoen W.R., Wyvratt M.J., Cheng K., Chan W.W.-S., Butler B., Jacks T.M., Hickey G.J., Schleim K.D., Leung K., Chen Z., Lee Chiu S.-H., Feeney W.P., Cunningham P.K., and Smith R.G. J. Med. Chem. 41 (1998) 1716
19. Guzikowski A.P., Whittemore E.R., Woodward R.M., Weber E., and Keana J.F.W. J. Med. Chem. 40 (1997) 2424
20. Fray J.M., Cooper K., Parry M.J., Richardson K., and Steele J. J. Med. Chem. 38 (1995) 3514
21. Seto M., Miyamoto N., Aikawa K., Aramaki Y., Kanzaki N., Iizawa Y., Baba M., and Shiraishi M. Bioorg. Med. Chem. 13 (2005) 363
22. Knockaert M., Wieking K., Schmitt S., Leost M., Grant K.M., Mottram J.C., Kunick C., and Meijer L. J. Biol. Chem. 277 (2002) 25493
23. Zuccotto F., Zvelebil M., Brun R., Chowdhury S.F., Di Lucrezia R., Leal I., Maes L., Ruiz-Perez L.M., Pacanowska D.G., and Gilbert I.H. Eur. J. Med. Chem. 36 (2001) 395
24. Gómez-Ayala S.L., Stashenko E., Palma A., Bahsas A., and Amaro-Luis J.M. Synlett 14 (2006) 2275
25. Yépez A.F., Palma A., Stashenko E., Bahsas A., and Amaro-Luis J.M. Tetrahedron Lett. 47 (2006) 5825
26. Kouznetsov V.V., Vargas L.Y., Leal S.M., Mora U., Coronado C.A., Meléndez C.M., Romero A.R., and Escobar P. Lett. Drug Des. Disc. 4 (2007) 293
27. 2-95% air mixture at 37 °C. After 24 h infected cultures were incubated with the compounds in a 3-fold dilution series in triplicate at each concentration for 72 h. Drug activity was determined from the percentage of infected cells in treated and untreated cultures in methanol-fixed and Giemsa-stained preparations. For mammalian cell toxicity: Vero cells or transformed THP-1 cells were incubated with the compound as above and the cell toxicity was analyzed following the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] reduction assay described by Mosmann, T. J. Immunol. Methods 1983, 65, 55.